Former MiMedX Execs Convicted On Securities Fraud Charges
The fraud caused the company’s annual revenue for 2015 to be inflated by about $8.2m
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
